6.99
price down icon6.80%   -0.51
pre-market  Pre-market:  6.83   -0.16   -2.29%
loading
Verastem Inc stock is traded at $6.99, with a volume of 2.16M. It is down -6.80% in the last 24 hours and up +12.92% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$7.50
Open:
$7.62
24h Volume:
2.16M
Relative Volume:
2.57
Market Cap:
$319.75M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.7007
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
+12.56%
1M Performance:
+12.92%
6M Performance:
+106.19%
1Y Performance:
-25.48%
1-Day Range:
Value
$6.85
$7.848
1-Week Range:
Value
$6.33
$8.12
52-Week Range:
Value
$2.10
$13.52

Verastem Inc Stock (VSTM) Company Profile

Name
Name
Verastem Inc
Name
Phone
(781) 292-4200
Name
Address
117 KENDRICK STREET, NEEDHAM, MA
Name
Employee
78
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
VSTM's Discussions on Twitter

Compare VSTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VSTM
Verastem Inc
6.99 319.75M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-25 Initiated Jefferies Buy
Mar-24-25 Reiterated H.C. Wainwright Buy
Dec-31-24 Reiterated BTIG Research Buy
Sep-30-24 Initiated Guggenheim Buy
Nov-21-23 Resumed BTIG Research Buy
Sep-27-23 Initiated B. Riley Securities Buy
Jun-15-23 Upgrade Mizuho Neutral → Buy
Sep-07-22 Resumed Alliance Global Partners Buy
Apr-29-22 Resumed Cantor Fitzgerald Overweight
Apr-14-22 Initiated RBC Capital Mkts Outperform
Mar-09-22 Initiated Truist Buy
Jul-01-21 Initiated Alliance Global Partners Buy
May-24-21 Upgrade BTIG Research Neutral → Buy
Jun-20-19 Downgrade BTIG Research Buy → Neutral
May-10-19 Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18 Initiated BTIG Research Buy
May-02-18 Initiated Seaport Global Securities Buy
Mar-08-18 Initiated B. Riley FBR, Inc. Buy
Sep-07-17 Reiterated H.C. Wainwright Buy
Apr-13-17 Initiated Oppenheimer Outperform
Mar-24-17 Reiterated H.C. Wainwright Buy
Sep-29-15 Downgrade Cantor Fitzgerald Buy → Hold
Sep-29-15 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15 Downgrade Jefferies Buy → Hold
Sep-29-15 Downgrade Raymond James Strong Buy → Outperform
Sep-28-15 Downgrade Mizuho Buy → Neutral
Sep-28-15 Downgrade ROTH Capital Buy → Neutral
Sep-09-15 Initiated Raymond James Strong Buy
May-12-15 Reiterated UBS Buy
Apr-08-15 Initiated H.C. Wainwright Buy
Jan-23-15 Reiterated ROTH Capital Buy
Jul-08-14 Resumed Oppenheimer Perform
Feb-11-14 Initiated Mizuho Buy
View All

Verastem Inc Stock (VSTM) Latest News

pulisher
Apr 28, 2025

Analyze Verastem Inc (NASDAQ: VSTM) Before Investing. - Stocksregister

Apr 28, 2025
pulisher
Apr 27, 2025

Verastem, Inc. (NASDAQ:VSTM) Shares Bought by Geode Capital Management LLC - Defense World

Apr 27, 2025
pulisher
Apr 26, 2025

Verastem Oncology rises on $75M private placement - MSN

Apr 26, 2025
pulisher
Apr 25, 2025

Verastem Oncology secures $75 million in private placement By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Verastem Inc [VSTM] Shares Rise 5.34 % on Thursday - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Merck cuts several Phase 2 programs; Vyne’s Phase 1b psoriasis trial put on clinical hold - Endpoints News

Apr 25, 2025
pulisher
Apr 25, 2025

Verastem Shares Rise After Agreement to Sell Securities Worth Roughly $75 Million - marketscreener.com

Apr 25, 2025
pulisher
Apr 25, 2025

Verastem Announces $75M Private Placement Agreement - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Verastem Oncology Announces $75 million Private Placement | VSTM Stock News - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Verastem Oncology Announces $75 million Private Placement - Bluefield Daily Telegraph

Apr 25, 2025
pulisher
Apr 25, 2025

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN

Apr 25, 2025
pulisher
Apr 25, 2025

12-Month Price Target For Verastem Inc (NASDAQ:VSTM) Now Sits At 14 - Marketing Sentinel

Apr 25, 2025
pulisher
Apr 23, 2025

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors - BioSpace

Apr 23, 2025
pulisher
Apr 23, 2025

Verastem (VSTM) Gains FDA Nod for Novel Cancer Drug VS-7375 - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Verastem (VSTM) Advances VS-7375 for Cancer Treatment with FDA A - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Verastem Oncology to initiate trial for its targeted cancer therapy (VSTM:NASDAQ) - Seeking Alpha

Apr 23, 2025
pulisher
Apr 23, 2025

Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

FDA clears Verastem’s new drug for clinical trial By Investing.com - Investing.com Canada

Apr 23, 2025
pulisher
Apr 23, 2025

There is no way Verastem Inc (VSTM) can keep these numbers up - Sete News

Apr 23, 2025
pulisher
Apr 23, 2025

(VSTM) Trading Report - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

Verastem Oncology to Report Q1 Earnings: What's in the Cards? - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

Verastem Inc (VSTM) rating initates by Jefferies - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Was there any good news for Verastem Inc (VSTM) stock in the last session? - uspostnews.com

Apr 22, 2025
pulisher
Apr 20, 2025

Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World

Apr 20, 2025
pulisher
Apr 16, 2025

Top Cancer Stocks to Buy to Boost Your Portfolio's Health - Yahoo Finance

Apr 16, 2025
pulisher
Apr 14, 2025

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 14, 2025
pulisher
Apr 11, 2025

Jefferies Initiates Coverage of Verastem (LSE:0LOV) with Buy Recommendation - Nasdaq

Apr 11, 2025
pulisher
Apr 11, 2025

Verastem (VSTM): Jefferies Initiates Coverage with Buy Rating Am - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (NASDAQ:VSTM) - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Jefferies Initiates Verastem at Buy With $15 Price Target - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Jefferies Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq

Apr 10, 2025
pulisher
Apr 10, 2025

Verastem stock initiated Buy at Jefferies (VSTM:NASDAQ) - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

Verastem (VSTM) Receives Buy Rating from Jefferies with Promisin - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Jefferies sets $15 price target on Verastem stock with Buy rating - Investing.com Canada

Apr 10, 2025
pulisher
Apr 09, 2025

Verastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

Mizuho Securities Adjusts Verastem Price Target to $8 From $9, Maintains Outperform Rating - marketscreener.com

Apr 08, 2025
pulisher
Apr 07, 2025

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Apr 07, 2025
pulisher
Apr 07, 2025

Verastem Oncology's Strategic Move: 247K Share Package Ties New Talent to Sales Goals - Stock Titan

Apr 07, 2025
pulisher
Apr 06, 2025

Where are the Opportunities in (VSTM) - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 02, 2025

Verastem Oncology Reports Progress in Cancer Treatments - TipRanks

Apr 02, 2025
pulisher
Apr 02, 2025

Verastem, Inc. (NASDAQ:VSTM) Short Interest Update - Defense World

Apr 02, 2025
pulisher
Mar 28, 2025

Verastem (NASDAQ:VSTM) Upgraded at StockNews.com - MarketBeat

Mar 28, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Has $457,000 Stake in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 25, 2025

Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire

Mar 25, 2025
pulisher
Mar 24, 2025

Verastem CFO Daniel Calkins sells shares worth $630 - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

Verastem CFO Daniel Calkins sells shares worth $630 By Investing.com - Investing.com Australia

Mar 24, 2025
pulisher
Mar 24, 2025

H.C. Wainwright lifts Verastem stock price target to $10 By Investing.com - Investing.com Canada

Mar 24, 2025
pulisher
Mar 24, 2025

Guggenheim lifts Verastem stock target to $14, maintains buy By Investing.com - Investing.com Canada

Mar 24, 2025

Verastem Inc Stock (VSTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Cap:     |  Volume (24h):